Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Hematologic/Leukemia

22nd Jan 2026

Plain language summary: results of pre-transplant inotuzumab ozogamicin treatment in acute lymphoblastic leukemia patients

22nd Jan 2025

Plain language summary of the ASCEMBL study: comparing asciminib and bosutinib after multiple prior treatments for chronic myeloid leukemia

This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at least once for, relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
22nd Jan 2024

Zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment- a plain language summary

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy